Print

NicOx SA (COX.PA): Patient Recruitment Completed by Bausch & Lomb in Glaucoma Study  
11/28/2011 9:31:36 AM

SOPHIA ANTIPOLIS, FRANCE--(Marketwire - November 28, 2011) -



PRESS RELEASE

NicOx: Patient recruitment completed by Bausch + Lomb in glaucoma study

www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced that the ongoing phase 2b study of BOL-303259-X, conducted by its partner Bausch + Lomb, has finished recruitment. Bausch + Lomb anticipates that the study will be completed by the end of December 2011, with preliminary results expected in the first quarter of 2012.

BOL-303259- is an NO-donating prostaglandin F2-alpha analog which is thought to lower intraocular pressure (IOP) through a dual mechanism of action. The ongoing study is intended to identify the most effective dose of BOL- 303259-X, administered in the evening to patients with open-angle glaucoma or ocular hypertension, for the reduction of IOP.

About NicOx

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NMEs) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

The Company's pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, who include Merck (known as MSD outside the United States and Canada), Bausch + Lomb, and Ferrer.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on NicOx's business are presented in the 4(th) chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2010 » filed with the French Autorité des Marchés Financiers (AMF) on February 25, 2011 and available on NicOx's website (www.nicox.com) and on the AMF's website (www.amf-france.org).

NICOX: Patient recruitment completed by Bausch + Lomb in glaucoma study: http://hugin.info/143509/R/1566780/486563.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NICOX via Thomson Reuters ONE

[HUG#1566780]


CONTACTS
NicOx
Gavin Spencer
Vice President Business Development
Tel +33 (0)4 97 24 53 00
Email Contact
www.nicox.com

Media Relations
FTI Consulting
Jonathan Birt
Tel : +44 (0)20 7269 7205
Email Contact

NicOx S.A.
Les Taissounieres
Bat HB4
1681 route des Dolines - BP313
06906 Sophia Antipolis Cedex - France
Tel: +33 (0)4 97 24 53 00
Fax: +33 (0)4 97 24 53 99


//-->